Nasdaq
$28.44▲ 0.16%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.06BShares out 37.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 10.5Pre-market26.10.05 20:328-KKey event#●●●#●●●
HARROW, INC.Bullish
Harrow has completed the acquisition of global rights, excluding Japan, for the dry eye disease treatment TYRVAYA from Viatris for $30 million in cash. The company may pay up to an additional $70 million in contingent milestone payments and expects TYRVAYA to contribute over $30 million in revenue in 2027.…more
$28.44+0.16%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.4After-hours26.09.05 05:458-KKey event
HARROW, INC.
Randall E. Pollard stepped down as Chief Accounting Officer and principal accounting officer of Harrow, Inc., effective September 4, 2026. Following his departure, Andrew R. Boll, the Company's President and CFO, has been appointed to serve as the principal accounting officer.…more
$28.44+0.16%vs prev closeView filingShare - 8.21After-hours26.08.22 07:32144Ownership
HARROW, INC.
Harrow, Inc. insider Amir Shojaei filed an SEC Form 144 on August 21, 2026, reporting a plan to sell company shares. This filing serves as an official notification of the insider's intent to dispose of their equity holdings.…more
$28.44+0.16%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5Pre-market26.10.05 20:00Bullish#●●●#●●●
Harrow Completes Acquisition of TYRVAYA Nasal Spray
Harrow has finalized its acquisition of the FDA-approved dry eye disease treatment TYRVAYA from Viatris to bolster its ocular surface franchise. The company expects the product to contribute over $30 million in revenue during 2027.…more
$28.44+0.16%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.30Pre-market26.09.30 20:00
●●●●●●●● ●●●●● ●●●●●●
Harrow announced that it will present 15 scientific abstracts, including Phase 3 trial results, at upcoming AAOpt and AAO meetings. While these presentations highlight the clinical evidence for its ophthalmic portfolio, they do not represent immediate financial or operational catalysts.…more
$28.44+0.16%vs prev close - 8.20Pre-market26.08.20 20:04
●●●●●●●● ●●●●● ●●●●●●
Harrow announced that its ophthalmic anesthetic IHEEZO demonstrated statistically significant results, reducing patient discomfort by approximately 58% compared to the control. While the clinical success validates the product's efficacy, its impact on future revenue remains to be seen.…more
$28.44+0.16%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report